Monoclonal Antibodies

Laboratory-made proteins designed to bind to specific markers found on the surface of cancer cells. Once bound, these antibodies can mark the cancer cell for destruction by the immune system, block signals the cancer cell needs to survive and grow, or, in some formulations, deliver a toxic payload directly to the cancer cell. Monoclonal antibodies are now a standard part of treatment for several types of lymphoma, leukemia, and multiple myeloma.

Immune Checkpoint Inhibitors

Cancer cells sometimes exploit natural "checkpoint" mechanisms that the immune system uses to avoid attacking the body's own healthy tissue, effectively hiding from immune detection. Checkpoint inhibitor drugs block these mechanisms, helping the immune system recognize and attack the cancer cells more effectively. These are used in select blood cancers, particularly certain types of lymphoma.

Bispecific Antibodies

A newer class of engineered antibodies designed to simultaneously bind to a cancer cell and a type of immune cell, effectively bringing the two together and triggering the immune cell to attack the cancer cell directly.

Antibody-Drug Conjugates

Monoclonal antibodies linked to a potent chemotherapy agent, allowing the drug to be delivered specifically to cancer cells that carry the target marker, potentially increasing effectiveness while reducing exposure of healthy cells to the chemotherapy component.

CAR-T Cell Therapy

An advanced and highly specialized form of immunotherapy in which a patient's own immune cells (T cells) are collected, genetically modified in a laboratory to better recognize cancer cells, multiplied, and then reinfused into the patient. This is a highly resource-intensive treatment currently available at a small number of specialized centers. For appropriately selected patients, Dr. Naim can help evaluate candidacy and coordinate referral to a center offering this therapy, while managing the patient's overall hematology care and follow-up locally.

Non-Hodgkin Lymphoma

Monoclonal antibodies are a cornerstone of treatment for several subtypes, often combined with chemotherapy in initial treatment and used alone in certain maintenance or relapsed settings.

Hodgkin Lymphoma

Checkpoint inhibitors and certain antibody-drug conjugates play a role, particularly in relapsed or refractory disease.

Chronic Lymphocytic Leukemia

Monoclonal antibody therapy is used both in combination with other treatments and, in some regimens, as part of chemotherapy-free approaches.

Multiple Myeloma

Several types of monoclonal antibodies and other immune-based therapies are now integrated into both initial treatment and relapsed disease management, often significantly improving depth of response.

Acute Lymphoblastic Leukemia

Certain bispecific antibodies and monoclonal antibody therapies have become important options, particularly for relapsed or hard-to-treat disease.

Confirmed Diagnosis and Specific Disease Markers

Since most immunotherapy drugs target specific proteins present on cancer cells, testing to confirm the presence of the relevant target marker is often necessary before treatment can be planned.

Disease Stage and Prior Treatment History

Whether immunotherapy is used as part of initial treatment, in combination with chemotherapy, or reserved for relapsed disease depends on the specific condition and established treatment protocols.

Overall Health and Organ Function

As with other cancer treatments, baseline health assessment helps determine which options are appropriate and how closely a patient needs to be monitored during treatment.

Discussion of Goals and Expectations

Since immunotherapy approaches, timelines, and potential outcomes can differ meaningfully from traditional chemotherapy, clear communication about what to expect is an important part of treatment planning.

Infusion Reactions

Some patients experience reactions during or shortly after infusion, ranging from mild (fever, chills) to more significant, which is why the first few doses are typically given with close monitoring.

Immune-Related Side Effects

Because immunotherapy works by modulating the immune system, it can occasionally cause the immune system to become overactive against healthy tissue, leading to inflammation in various organs. Recognizing and promptly managing these effects is an important part of ongoing care.

Increased Infection Risk

Certain immunotherapy drugs can affect normal immune cell populations, increasing susceptibility to specific types of infection, which requires monitoring and sometimes preventive measures.

Cytokine Release Syndrome

A specific and potentially serious reaction associated with certain highly active immune-based therapies, such as bispecific antibodies and CAR-T cell therapy, requiring specialized monitoring protocols, particularly in the days following treatment.